|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-2-3
|
|
pubmed:abstractText |
Platelet-activating factor (PAF) and structurally-related oxidized phospholipids are proinflammatory mediators in systemic inflammatory states such as severe sepsis. The enzyme platelet-activating factor acetylhydrolase (PAF-AH) rapidly degrades PAF and oxidized phospholipids into inactive metabolites. Reduced PAF-AH activity has been observed in patients with severe sepsis and may contribute to their systemic inflammatory response and organ dysfunction. A previous clinical trial with recombinant human PAF-AH (rPAF-AH, Pafase) suggested that this treatment may decrease 28-day all-cause mortality in patients with severe sepsis. The current study was undertaken to confirm this result.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0090-3493
|
|
pubmed:author |
pubmed-author:AbrahamEdwardE,
pubmed-author:Controlled Mortality Trial of Platelet-Activating Factor...,
pubmed-author:DemeyerIgnaceI,
pubmed-author:DhainautJean-FrancoisJF,
pubmed-author:DugernierThierryT,
pubmed-author:FrancoisBrunoB,
pubmed-author:JaureguiLuisL,
pubmed-author:KljucarSaschaS,
pubmed-author:LaterrePierre-FrancoisPF,
pubmed-author:LopezAngelA,
pubmed-author:LorenteJose AngelJA,
pubmed-author:LowryStephenS,
pubmed-author:McGeeWilliamW,
pubmed-author:OpalStevenS,
pubmed-author:PribbleJohnJ,
pubmed-author:ReinhartKonradK,
pubmed-author:SanchezMiguelM,
pubmed-author:SouzaSoniaS,
pubmed-author:WarrenBrianB,
pubmed-author:WitteboleXavierX
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
332-41
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
|
|
pubmed:affiliation |
Division of Infectious Diseases, Brown Medical School, Providence, RI, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
